Urogen Pharma (NASDAQ:URGN) Stock Price Target Cut by Guggenheim

Urogen Pharma (NASDAQ:URGN) had its price target dropped by research analysts at Guggenheim from $58.00 to $56.00 in a report issued on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Guggenheim‘s price target suggests a potential upside of 126.26% from the stock’s previous close.

A number of other research analysts have also issued reports on URGN. Oppenheimer set a $60.00 price objective on Urogen Pharma in a research report on Thursday. TD Cowen raised their target price on Urogen Pharma from $50.00 to $60.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Jefferies Financial Group reissued a “buy” rating and set a $56.00 price target on shares of Urogen Pharma in a report on Thursday, September 10th. HC Wainwright restated a “buy” rating and set a $75.00 price target on shares of Urogen Pharma in a research report on Monday, October 19th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Urogen Pharma in a report on Thursday, October 15th. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $53.38.

Urogen Pharma Stock Down 3.8%

Shares of URGN traded down $0.98 during midday trading on Thursday, hitting $24.75. The company had a trading volume of 1,758,050 shares, compared to its average volume of 1,169,568. Urogen Pharma has a 52 week low of $16.50 and a 52 week high of $50.81. The company’s 50 day moving average price is $38.78 and its 200 day moving average price is $31.53. The stock has a market cap of $1.21 billion, a price-to-earnings ratio of -18.75 and a beta of 1.68.

Urogen Pharma (NASDAQ:URGN) last issued its earnings results on Wednesday, November 4th. The company reported ($0.03) earnings per share for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.14). The business had revenue of $89.00 million for the quarter, compared to the consensus estimate of $89.92 million. Equities analysts anticipate that Urogen Pharma will post -0.20 EPS for the current fiscal year.

Insider Buying and Selling at Urogen Pharma

In other Urogen Pharma news, CFO Chris Degnan sold 2,202 shares of the business’s stock in a transaction dated Thursday, October 8th. The shares were sold at an average price of $36.69, for a total transaction of $80,791.38. Following the sale, the chief financial officer directly owned 4,561 shares in the company, valued at approximately $167,343.09. The trade was a 32.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel Jason Smith sold 1,519 shares of the firm’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $42.54, for a total value of $64,618.26. Following the transaction, the general counsel directly owned 53,141 shares of the company’s stock, valued at $2,260,618.14. This represents a 2.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 65,269 shares of company stock valued at $3,037,646. Company insiders own 4.80% of the company’s stock.

Hedge Funds Weigh In On Urogen Pharma

Several large investors have recently made changes to their positions in the business. JW Asset Management LLC bought a new stake in shares of Urogen Pharma in the 3rd quarter worth approximately $813,000. Russell Investments Group Ltd. boosted its holdings in Urogen Pharma by 92.8% during the third quarter. Russell Investments Group Ltd. now owns 183,076 shares of the company’s stock worth $7,438,000 after buying an additional 88,097 shares in the last quarter. CenterBook Partners LP acquired a new position in Urogen Pharma in the third quarter worth approximately $642,000. Calamos Advisors LLC bought a new position in shares of Urogen Pharma in the third quarter valued at $246,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Urogen Pharma during the third quarter worth $101,000. Institutional investors own 91.29% of the company’s stock.

Key Stories Impacting Urogen Pharma

Here are the key news stories impacting Urogen Pharma this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to a loss of $0.77 from a loss of $0.83, and lifted its Q4 2026 and Q1 2027 forecasts to $0.02 per share. The firm maintained its Buy rating and $75 target. Analysts Offer Insights on Healthcare Companies
• Neutral Sentiment: Sell-side brokerages collectively rate URGN “Moderate Buy,” though that consensus provides limited near-term direction. Urogen Pharma Stock Now Rated Moderate Buy
• Negative Sentiment: HC Wainwright cut its FY2027 EPS forecast to $0.59 from $1.05, lowering estimates for Q2, Q3 and Q4 2027 as well. The reductions suggest a less favorable profit outlook, despite the firm’s unchanged Buy rating and target.
• Negative Sentiment: The latest quarterly results missed expectations: UroGen reported a $0.03-per-share loss versus consensus earnings of $0.11, while revenue of $89 million was slightly below estimates. Reports said shares fell sharply after the results and slipped below their 200-day moving average. Shares Break Below Two Hundred Day Moving Average on Disappointing Earnings

Urogen Pharma Company Profile

UroGen Pharma Ltd. (NASDAQ: URGN) is a biopharmaceutical company focused on developing and commercializing treatments for cancers of the urinary tract. The company’s therapies are designed to deliver medicines directly to the affected area, with the goal of improving drug exposure while limiting systemic side effects.

UroGen’s primary commercial product is Jelmyto, a mitomycin-based treatment approved in the United States for adults with low-grade upper tract urothelial cancer. Jelmyto uses UroGen’s proprietary RTGel technology, which forms a gel in the urinary tract and enables the sustained local release of mitomycin.

The company has also developed UGN-102, an investigational mitomycin-based reverse thermal gel intended for the treatment of low-grade, intermediate-risk non-muscle-invasive bladder cancer.